BiomX(PHGE) - 2025 Q2 - Quarterly Results

Exhibit 99.1 ● BiomX reported positive topline results from the Phase 2 trial of BX211 in March 2025 just prior to the start of the second quarter, demonstrating that BX211 was safe and well-tolerated and produced sustained and statistically significant percentage area reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13) with separation from placebo starting at week 7 and a difference greater than 40% by week 10. BX004 – Fixed phage cocktail for chronic Pseudomonas aeruginosa (P. aerugin ...